Ernexa Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $10.13 million. The enterprise value is $9.08 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 52.24 million shares outstanding. The number of shares has increased by 156.81% in one year.
| Current Share Class | 52.24M |
| Shares Outstanding | 52.24M |
| Shares Change (YoY) | +156.81% |
| Shares Change (QoQ) | +609.02% |
| Owned by Insiders (%) | 67.77% |
| Owned by Institutions (%) | 4.33% |
| Float | 10.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.54 |
| Forward PS | n/a |
| PB Ratio | 5.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.40.
| Current Ratio | 0.80 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.55 |
Financial Efficiency
Return on equity (ROE) is -2,264.31% and return on invested capital (ROIC) is -46.41%.
| Return on Equity (ROE) | -2,264.31% |
| Return on Assets (ROA) | -39.64% |
| Return on Invested Capital (ROIC) | -46.41% |
| Return on Capital Employed (ROCE) | -740.03% |
| Revenue Per Employee | $97,000 |
| Profits Per Employee | -$7.43M |
| Employee Count | 6 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ERNA has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.94% in the last 52 weeks. The beta is 7.37, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 7.37 |
| 52-Week Price Change | -90.94% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 43.69 |
| Average Volume (20 Days) | 214,645 |
Short Selling Information
The latest short interest is 210,971, so 0.40% of the outstanding shares have been sold short.
| Short Interest | 210,971 |
| Short Previous Month | 369,164 |
| Short % of Shares Out | 0.40% |
| Short % of Float | 1.99% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
In the last 12 months, ERNA had revenue of $582,000 and -$44.56 million in losses. Loss per share was -$3.26.
| Revenue | 582,000 |
| Gross Profit | 486,000 |
| Operating Income | -17.25M |
| Pretax Income | -22.90M |
| Net Income | -44.56M |
| EBITDA | -17.11M |
| EBIT | -17.25M |
| Loss Per Share | -$3.26 |
Full Income StatementBalance Sheet
The company has $1.73 million in cash and $684,000 in debt, giving a net cash position of $1.05 million or $0.02 per share.
| Cash & Cash Equivalents | 1.73M |
| Total Debt | 684,000 |
| Net Cash | 1.05M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 1.70M |
| Book Value Per Share | 0.03 |
| Working Capital | -586,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.84 million and capital expenditures -$369,000, giving a free cash flow of -$16.21 million.
| Operating Cash Flow | -15.84M |
| Capital Expenditures | -369,000 |
| Free Cash Flow | -16.21M |
| FCF Per Share | -$0.31 |
Full Cash Flow StatementMargins
| Gross Margin | 83.51% |
| Operating Margin | -2,963.92% |
| Pretax Margin | -7,647.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |